HopeStage
Back to all studies
CompletedNCT01039454

How GSK598809 affects brain responses to food reward

About this titleRead the official source — NCT01039454
Medication studyAges 18–45United KingdomAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 45 years.

Listed locations
Cambridge and 1 more locationSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 18, 2008
Recruitment status
Completed
Enrollment listed in the registry
24
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 45 Years
Official registry ID
NCT01039454
Official title
Show the full official title

A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cambridge · London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including GSK598809 Capsules and GSK598809 Placebo Capsules.

Who was this study for?

Listed age limits: 18 years to 45 years.

Want to explore more studies?

Explore studies